发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations. 靶向嵌合体（PROTACs）在肿瘤学中的蛋白水解：专利和监管考虑的回顾。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-05-15 DOI: 10.1080/20468954.2025.2500809
Sowndharya M, Ramesh Joga, Kajal Gandhi, Sravani Yerram, Rajeev Singh Raghuvanshi, Saurabh Srivastava
{"title":"Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations.","authors":"Sowndharya M, Ramesh Joga, Kajal Gandhi, Sravani Yerram, Rajeev Singh Raghuvanshi, Saurabh Srivastava","doi":"10.1080/20468954.2025.2500809","DOIUrl":"10.1080/20468954.2025.2500809","url":null,"abstract":"<p><strong>Introduction: </strong>Proteolysis Targeting Chimeras (PROTACs) represents a groundbreaking advancement in drug discovery and targeted protein degradation. Unlike traditional small-molecule inhibitors, PROTACs leverage the cell's natural protein degradation machinery to selectively degrade pathogenic proteins, offering significant therapeutic potential for previously undruggable targets and complex diseases such as cancer and neurodegenerative disorders. Understanding the regulatory landscape governing their approval is crucial as their development accelerates.</p><p><strong>Areas covered: </strong>This review provides an overview of recent patents, regulatory considerations, emerging concerns, and future perspectives of PROTACs in cancer management.</p><p><strong>Expert opinion: </strong>From a regulatory perspective, PROTACs present unique challenges and opportunities. Their dual-functional nature requires a nuanced approach to classification and approval, blending small-molecule and biologic regulatory frameworks. Specific guidelines addressing pharmacokinetic and pharmacodynamic profiles are needed. Comprehensive preclinical evaluation and robust clinical trial designs are essential to manage off-target effects and immunogenic responses. The collaboration between regulatory bodies, academia, and industry is crucial for establishing a clear pathway for PROTAC approval. Future considerations must account for advancements in PROTAC technology to ensure safe and effective therapies reach patients. While PROTACs hold immense promise, their regulatory journey requires tailored guidelines and rigorous evaluation to realize their full potential.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"187-199"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights October-November 2023. 2023 年 10 月至 11 月的专利要点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2024-09-04 DOI: 10.1080/20468954.2024.2389765
Hermann Am Mucke
{"title":"Patent highlights October-November 2023.","authors":"Hermann Am Mucke","doi":"10.1080/20468954.2024.2389765","DOIUrl":"https://doi.org/10.1080/20468954.2024.2389765","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"13 1-3","pages":"23-29"},"PeriodicalIF":1.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment. 三特异性抗cldn -18.2/CD3/CD28抗体治疗胃癌。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-08-05 DOI: 10.1080/20468954.2025.2535943
Donaciano Flores-Robles, Antonio Celestino Montes, Jorge Antonio Perez Saldaña, Vanessa Del Razo-González, Gabriela Sanchez-Esgua, Martin Perez-Santos
{"title":"Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment.","authors":"Donaciano Flores-Robles, Antonio Celestino Montes, Jorge Antonio Perez Saldaña, Vanessa Del Razo-González, Gabriela Sanchez-Esgua, Martin Perez-Santos","doi":"10.1080/20468954.2025.2535943","DOIUrl":"10.1080/20468954.2025.2535943","url":null,"abstract":"<p><p>Claudin-18.2 is an overexpressed molecule in gastric cancer, which is why it is considered a potential therapeutic target. WO2024082060 describes trispecific antibodies directed against CDLN-18.2/CD3/CD28, and gastric cancer treatment method. These antibodies exhibit cytotoxic activity, in coculture with primary human CD3+ T lymphocytes, against gastric cancer cells expressing CLDN-18.2, as well as an inhibition of tumor growth rate in a murine model of gastric cancer. The trispecific structure, in particular the CD3 and CD28 binding domains, induce optimal co-stimulation of effector T cells, suggesting that these antibodies are potential candidates for clinical trials for the treatment of gastric cancer associated with high levels of CDLN-18.2 expression.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"161-168"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144785004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions. 从补充剂到超级细菌：益生菌专利差距如何推动抗菌素耐药性和CRISPR-Cas解决方案。
IF 2.1
Pharmaceutical patent analyst Pub Date : 2024-01-01 Epub Date: 2025-02-05 DOI: 10.1080/20468954.2025.2459592
Absar Talat, Asad U Khan
{"title":"From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions.","authors":"Absar Talat, Asad U Khan","doi":"10.1080/20468954.2025.2459592","DOIUrl":"10.1080/20468954.2025.2459592","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"91-93"},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proposed supplementary protection certificate legislation for medicinal products. 拟议的医药产品补充保护证书立法。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0031
Olivia J Creemer, Stephen Garner
{"title":"Proposed supplementary protection certificate legislation for medicinal products.","authors":"Olivia J Creemer, Stephen Garner","doi":"10.4155/ppa-2023-0031","DOIUrl":"10.4155/ppa-2023-0031","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"249-252"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Highlights April-May 2023. 2023 年 4 月至 5 月的专利亮点。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0028
Hermann Am Mucke
{"title":"Patent Highlights April-May 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0028","DOIUrl":"10.4155/ppa-2023-0028","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"253-259"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progression and expansion of quinoline as bioactive moiety: a patent review. 作为生物活性分子的喹啉的进步与发展：专利回顾。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-31 DOI: 10.4155/ppa-2023-0025
Yash Chauhan, Kumari Neha, Sharad Wakode, Mohd Shahfaiz, Ramesh B Bodla, Kalicharan Sharma
{"title":"Progression and expansion of quinoline as bioactive moiety: a patent review.","authors":"Yash Chauhan, Kumari Neha, Sharad Wakode, Mohd Shahfaiz, Ramesh B Bodla, Kalicharan Sharma","doi":"10.4155/ppa-2023-0025","DOIUrl":"10.4155/ppa-2023-0025","url":null,"abstract":"<p><p>Quinoline inhibitors are appealing medicinal products for a range of illnesses and problems. It is bicyclic heterocyclic scaffold has been intensively employed in pharmacological research and is well known for its wide range of biological purposes. Biological activities exhibited by quinoline derivatives, such as anti-inflammatory properties, antioxidant, antimicrobial, anti-tubercular, antidiabetic, anti-malarial and others are covered in detail in this review. The IC<sub>50</sub> of patented inhibitors might range from nm to μM range, based on the experiments used. It presents an outline of patents file between 2002 and 2023 concerning to biological activities by quinoline derivatives. As a result, it is critical to develop additional chemical quinoline core alterations for novel chemical compounds and enhanced pharmacological impacts.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"287-314"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139642691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patenting trends by Mexican pharmaceutical companies. 墨西哥制药公司的专利申请趋势。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0029
Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Martin Perez-Santos
{"title":"Patenting trends by Mexican pharmaceutical companies.","authors":"Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Martin Perez-Santos","doi":"10.4155/ppa-2023-0029","DOIUrl":"10.4155/ppa-2023-0029","url":null,"abstract":"<p><p><b>Aim:</b> the activity of patent claims by Mexican pharmaceutical companies is unknown. <b>Objective:</b> analyse the trend in patents of Mexican pharmaceutical companies. <b>Method:</b> a search for patents was carried out in the patent database of the Mexican Institute of Industrial Property, using the list of Mexican pharmaceutical companies belonging to the Mexican Association of Pharmaceutical Research Industries, and the codes A61K, A61P and C07 of the International Patent Classification. <b>Results:</b> the leading companies in patent applications were Liomont, Senosiain and RIMSA; however, Mexican pharmaceutical companies claim very few patents, only 266 patent applications in the period 2000-2020, with a technological factor with a value of zero, and a commercial factor of little value. <b>Conclusion:</b> Mexican pharmaceutical companies lack a robust patent system, without growth, and with a low percentage of patents with high commercial value.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"275-286"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer. 基于脂质的介孔二氧化硅纳米粒子：胰腺癌治疗模式的转变。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-11-01 Epub Date: 2024-01-12 DOI: 10.4155/ppa-2023-0024
Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar
{"title":"Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer.","authors":"Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar","doi":"10.4155/ppa-2023-0024","DOIUrl":"10.4155/ppa-2023-0024","url":null,"abstract":"<p><p>Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic efficacy in treating this disease. Low or limited drug loading capacity is another problem with current chemotherapeutic agents. There is a need to develop novel approaches to overcome these issues. Hence, an innovative approach has been proposed to co-deliver both hydrophilic (Gemcitabine) and hydrophobic (Paclitaxel) drugs in a single carrier using lipid bilayer-mesoporous silica nanoparticles (LB-MSNP). MSNPs offer effective drug delivery due to their superior bioavailability and physicochemical properties. Further, in order to achieve clinical translation and regulatory approval, toxicity and biodegradability of MSNPs must be resolved.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"261-273"},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence. 生物反应性DNA纳米茧在治疗术后癌症复发中的突出作用。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0013
Sravani Yerram, Ramesh Joga, Pooja Shende, Priya Varpe, Kiran Kumar Bellapu, Sandeep Kumar
{"title":"Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence.","authors":"Sravani Yerram, Ramesh Joga, Pooja Shende, Priya Varpe, Kiran Kumar Bellapu, Sandeep Kumar","doi":"10.4155/ppa-2023-0013","DOIUrl":"10.4155/ppa-2023-0013","url":null,"abstract":"<p><p>Post-surgery cancer recurrence is one of the reasons for increased cancer cases. The effective usage of the enhanced permeability and retention effect of a nanocarrier infused with the bioresponsive release mechanism of checkpoint inhibitors (aPD1 and aCTLA4) can become a boon to mankind. DNA nanococoons (DNCs) comprising cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODNs) with potent immunostimulatory effects can significantly enhance anti-cancer activity. Triglycerylmonostearate (TGMS) with enzymatic cleavage potential at the wound sites of tumor resection, upon caging with restriction enzyme (HhaI) followed by attaching to DNCs, makes the immunotherapy bioresponsive. Hhal-TGMS-DNCs-aPD1 triggered by the inflammation at the wound site undergoes enzymatic cleavage, releases the restriction enzyme, converts DNCs to CpG ODNs sequentially and with sustained aPD1 release exerts an appreciable anti-cancer effect.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"219-229"},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信